APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics

Documenti analoghi

• Efficacy and Safety of Oral Valiltramiprosate in APOE4/4 Homozygotes with Early AD: Topline Results from the APOLLOE4 Phase 3 Trial
  di: Aidan Power, et al.
  Pubblicazione: (2025)
• Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in the Pre‐Specified MCI Group: Subgroup Analysis from the 78‐Week APOLLOE4 Phase 3 Trial in APOE4/4 Homozygotes
  di: Susan Abushakra, et al.
  Pubblicazione: (2025)
• Valiltramiprosate Effects on Microstructural Integrity of Grey and White Matter in APOE4/4 Homozygotes with Early AD and their Correlations to Clinical Outcomes: MRI Mean Diffusivity Results from the 78‐Week APOLLOE4 Phase 3 Trial
  di: Earvin Liang, et al.
  Pubblicazione: (2025)
• Valiltramiprosate/ALZ‐801 Prevents Hippocampal Atrophy and Clinical Decline in a Stage 2 AD Subpopulation in APOLLOE4 Phase 3 Study
  di: Jeremy Yu, et al.
  Pubblicazione: (2025)
• Quantitative System Pharmacology Analysis of Oral Valiltramiprosate/ALZ‐801 Predicts Slowing of Alzheimer’s Disease Progression by Anti‐Amyloid Oligomer and APOE4 Structural Corrector Modes of Action
  di: Jean Schaefer, et al.
  Pubblicazione: (2025)